Artivion (AORT) Form 4: CEO Disposes 12,500 Shares; Retains 852,783
Rhea-AI Filing Summary
James P. Mackin, President & CEO and director of Artivion, Inc. (AORT), reported a sale of common stock on 08/15/2025. The Form 4 shows he sold 12,500 shares at a weighted average price of $42.319 (prices ranged $42.25 to $42.585). After the transaction he beneficially owned 852,783 shares. The filing is signed 08/19/2025 and the reporting person notes availability of per-price sale details upon request.
Positive
- Reporting compliance: The insider filed Form 4 with transaction date, amounts, price range, and signature, meeting disclosure requirements
- Significant retained ownership: The reporting person still beneficially owns 852,783 shares, indicating continued substantial stake
Negative
- Insider sale: The CEO sold 12,500 shares on 08/15/2025, which may be interpreted by some investors as a liquidity event
- Price range disclosed but not per-lot detail: The filing provides a weighted average ($42.319) and range ($42.25–$42.585) but not the exact allocation at each price without request
Insights
TL;DR: CEO sold a small portion of holdings; retains a large ownership base of 852,783 shares.
The Form 4 discloses an open-market sale of 12,500 common shares on 08/15/2025 at a weighted average price of $42.319. The volume sold represents roughly 1.47% of the post-transaction beneficial holding level reported. Transaction codes indicate a standard sale; no derivatives or related-plan executions are reported. For investors, the transaction is a liquidity event by the insider but not a divestiture of a controlling position given the remaining stake.
TL;DR: Routine insider sale disclosed properly with price range noted and availability of detailed allocation on request.
The filing complies with Section 16 reporting: it lists the relationship (President & CEO and director), the transaction date, the number of shares sold, and a weighted average price with a disclosed price range. The signature and remark about providing per-price sale details on request increase transparency. There is no indication of Rule 10b5-1 plan reliance checked on the form.